Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe

News Update


Biotech Collaborates to Advance Psychedelics Use in Cancer, Other Applications
News Update

Share on Stocktwits


Revive Therapeutics enters an agreement with PharmaTher, a specialty psychedelics pharmaceutical firm.

Revive Therapeutics Ltd. (RVV:TSX.V; RVVTF:OTCMKTS) announced in a news release it entered an agreement with PharmaTher Inc. to accelerate building a pipeline of psychedelic drugs for cancer treatment and to discover novel uses of psychedelic compounds.

PharmaTher, a subsidiary of Newscope Capital, is a specialty psychedelics pharmaceutical company with a psilocybin cancer program and a psychedelics drug repurposing artificial intelligence (AI) platform called panaceAI.

Revive notes that the collaboration will afford it exclusivity to pursue two major development avenues. One is developing PharmaTher's recent discovery concerning psilocybin's potential to treat certain cancers, including liver, breast, kidney, melanoma and acute myeloid leukemia, and ultimately expand Revive's psychedelics drug pipeline in the cancer arena.

The other is to leverage PharmaTher's panaceAI to discover new targets of psychedelic compounds for possible use with Revive's oral thin film delivery technology.

"Revive continues to be focused on developing novel uses for psilocybin that leverages our proprietary oral thin film delivery technology as a differentiated therapeutic approach," said Michael Frank, CEO of Revive.


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Revive Therapeutics. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Revive Therapeutics, a company mentioned in this article.

Want to read more about Medical Devices and Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe